Vandazole is a drug owned by Teva Pharmaceuticals Usa. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 22, 2024. Details of Vandazole's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7456207 | Vaginal pharmaceutical compositions and methods for preparing them |
Sep, 2024
(3 months ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vandazole's patents.
Latest Legal Activities on Vandazole's Patents
Given below is the list of recent legal activities going on the following patents of Vandazole.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 23 Dec, 2016 | US7456207 |
| Patent Issue Date Used in PTA Calculation Critical | 25 Nov, 2008 | US7456207 |
| Recordation of Patent Grant Mailed Critical | 25 Nov, 2008 | US7456207 |
| Issue Notification Mailed Critical | 05 Nov, 2008 | US7456207 |
| Dispatch to FDC | 24 Oct, 2008 | US7456207 |
| Application Is Considered Ready for Issue Critical | 17 Oct, 2008 | US7456207 |
| Issue Fee Payment Verified Critical | 09 Oct, 2008 | US7456207 |
| Issue Fee Payment Received Critical | 09 Oct, 2008 | US7456207 |
| Mail Examiner's Amendment | 22 Sep, 2008 | US7456207 |
| Mail Notice of Allowance Critical | 22 Sep, 2008 | US7456207 |
US patents provide insights into the exclusivity only within the United States, but Vandazole is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vandazole's family patents as well as insights into ongoing legal events on those patents.
Vandazole's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Vandazole's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 22, 2024 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vandazole Generic API suppliers:
Metronidazole is the generic name for the brand Vandazole. 38 different companies have already filed for the generic of Vandazole, with Alembic having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Vandazole's generic
Alternative Brands for Vandazole
There are several other brand drugs using the same active ingredient (Metronidazole) as Vandazole. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Bausch |
| |
| Chemo Research Sl |
| |
| Galderma Labs Lp |
| |
| Labs Juvise |
| |
| Pfizer |
| |
| Saptalis Pharms |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Metronidazole, Vandazole's active ingredient. Check the complete list of approved generic manufacturers for Vandazole
About Vandazole
Vandazole is a drug owned by Teva Pharmaceuticals Usa. Vandazole uses Metronidazole as an active ingredient. Vandazole was launched by Teva Pharms in 2005.
Approval Date:
Vandazole was approved by FDA for market use on 20 May, 2005.
Active Ingredient:
Vandazole uses Metronidazole as the active ingredient. Check out other Drugs and Companies using Metronidazole ingredient
Dosage:
Vandazole is available in gel form for vaginal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.75% | GEL | Prescription | VAGINAL |